NCT07197255 Transcriptomic Profiling of Cumulus Cells From CAPA-IVM
| NCT ID | NCT07197255 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mỹ Đức Hospital |
| Condition | PCOS (Polycystic Ovary Syndrome) |
| Study Type | OBSERVATIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-10-16 |
| Primary Completion | 2026-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10 participants in total. It began in 2025-10-16 with a primary completion date of 2026-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Capacitation in vitro maturation (CAPA-IVM) has improved oocyte maturation and resulted in live births. Because cumulus cells (CCs) communicate bidirectionally with the oocyte, their transcriptomic profile may serve as a non-invasive biomarker of oocyte and embryo competence. This prospective pilot study will analyze CCs gene expression after CAPA-IVM using RNA sequencing and pathway analysis, and correlate findings with embryological outcomes including fertilization, day-3 cleavage, and blastocyst formation. Results are expected to provide insights into the molecular basis of oocyte competence and support development of non-invasive embryo selection strategies.
Eligibility Criteria
Inclusion Criteria: * Women 18-38 years * BMI =\< 32kg/m2 * Diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam 2003 criteria, meet at least 2 of the following 3 features: (1) Oligo-ovulation or anovulation. (2) Clinical and/or biochemical signs of hyperandrogenism (3) Polycystic ovarian morphology on ultrasound. * Indicated for CAPA-IVM treatment. * Serum AMH ≥ 4 ng/mL (28.57 pmol/L). * Antral follicle count (AFC) ≥ 24 follicles in both ovaries at the time of CAPA-IVM indication. * Signed informed consent to participate in the study. Exclusion Criteria: * Retrieved sperm from surgical procedures * Previous IVF cycle with total immature oocytes
Contact & Investigator
Lan N Vương, PhD, MD
PRINCIPAL INVESTIGATOR
University of Medicine and Pharmacy at Ho Chi Minh City
Frequently Asked Questions
Who can join the NCT07197255 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 38 Years, studying PCOS (Polycystic Ovary Syndrome). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07197255 currently recruiting?
Yes, NCT07197255 is actively recruiting participants. Contact the research team at huy.ph@myduchospital.vn for enrollment information.
Where is the NCT07197255 trial being conducted?
This trial is being conducted at Ho Chi Minh City, Vietnam.
Who is sponsoring the NCT07197255 clinical trial?
NCT07197255 is sponsored by Mỹ Đức Hospital. The principal investigator is Lan N Vương, PhD, MD at University of Medicine and Pharmacy at Ho Chi Minh City. The trial plans to enroll 10 participants.